-
The particles were characterized according to particle size, hydrodynamic size, zeta potential, purity, crystal status, and specific surface area. Figure 1 shows TEM images of the silica NPs and silica MPs. The appearance of silica NPs and silica MPs was approximately spherical. The size of silica NPs and silica MPs were 25.9 ± 3.4 nm and 1087.8 ± 389.6 nm, respectively. Silica NPs tended to aggregate/agglomerate in deionized water, with a hydrodynamic size of 246.6 ± 47.8 nm. The zeta potential of silica NPs and silica MPs were -64.1 mV and -63.0 mV, respectively. The pH value of silica NPs and silica MPs suspensions were 6.7 and 6.4, respectively. The purity of silica NPs and silica MPs were 99.2% and 99.6%, respectively. The crystal structures of silica NPs and silica MPs were both amorphous. The specific surface area of silica NPs and silica MPs were 152.2 m2/g and 4.4 m2/g, respectively.
-
The dissolution concentrations of silica NPs and silica MPs were 0.010% ± 0.002% and 0.015% ± 0.006%, respectively, in the simulated gastric solution and 0.420% ± 0.007% and 0.361% ± 0.052%, respectively, in the intestinal solution.
-
No mortality or treatment related adverse clinical reactions were found during the study. There were no statistically significant differences in the body weights of male rats between the treatment groups and the control group; however, for low-dose silica NPs in female rats, body weight at the fifth week of exposure was lower than that in the control group (Figure 2A). For middle-dose silica MPs in female rats, food consumption at the eighth week was lower than that in the control group. For low-dose silica NPs in male rats, food consumption at the 11th week was lower than that in the low-dose silica MPs group (Figure 2B).
Figure 2. General observations of subchronic oral toxicity of silica NPs and silica MPs in rats. (A) Mean body weights of rats. (B) Mean food consumption of rats. *Significant difference vs. control group, P < 0.05 (body weight of female rats at the fifth week, food consumption of female rats at the eighth week), #Significant difference vs. silica MPs 166.7 mg/(kg·bw) group, P < 0.05 (food consumption of male rats at the 11th week).
-
There were some sporadic, statistically significant changes in hematology and clinical biochemistry parameters (Table 1).
Table 1. Summary of Statistically Significant Hematology and Clinical Biochemical Parameters for Rats after 90 Days Oral Administration of Silica MPs and Silica NPs
Parameters Control Silica MPs, mg/(kg·bw) Silica NPs, mg/(kg·bw) 166.7 500 1, 500 166.7 500 1, 500 Female MCH (pg) 19.1 ± 1.2 18.3 ± 0.7 18.7 ± 0.6 18.5 ± 0.6 18.3 ± 0.6 17.7 ± 1.0* 18.7 ± 0.2 Cl (mmol/L) 120.7 ± 1.8 118.6 ± 2.0 119.6 ± 1.5 121.6 ± 1.1 120.0 ± 1.8 119.0 ± 2.1 118.1 ± 1.4*# Na (mmol/L) 125.1 ± 2.0 120.2 ± 1.2* 121.0 ± 2.5* 123.8 ± 2.7 122.2 ± 2.3* 122.6 ± 1.0 121.6 ± 1.0* T4 (ng/mL) 28.1 ± 6.6 30.8 ± 7.6 28.5 ± 3.9 27.8 ± 7.7 23.7 ± 7.2 32.1 ± 12.9 39.5 ± 6.4*# Male PT (s) 10.0 ± 0.4 10.0 ± 0.3 9.6 ± 0.4 9.9 ± 0.4 10.5 ± 0.5* 9.5 ± 0.3 9.8 ± 0.2 APTT (s) 59.2 ± 3.0 56.5 ± 2.8 58.4 ± 1.9 60.2 ± 1.8 60.1 ± 2.2# 57.3 ± 1.6 57.0 ± 1.9# TP (g/L) 50.9 ± 2.1 49.5 ± 1.7 55.7 ± 3.4* 54.9 ± 2.6* 55.1 ± 1.1*# 54.0 ± 2.4 52.8 ± 3.2 ALB (g/L) 27.0 ± 1.1 26.0 ± 0.9 27.3 ± 1.3 26.8 ± 1.3 26.8 ± 0.9 26.6 ± 1.1 25.3 ± 1.5* Na (mmol/L) 121.8 ± 2.8 121.6 ± 0.9 122.8 ± 2.0 124.0 ± 3.3 124.9 ± 1.5# 122.6 ± 1.5 121.7 ± 1.2 Note.*P < 0.05 as compared with the control group. #P < 0.05 as compared with the silica MPs group. For female rats in the silica NPs middle-dose group, the MCH was significantly lower than that in the control group. For male rats in the silica NPs low-dose group, PT was significantly higher than that in the control group, APTT was significantly higher than that in the silica MPs low-dose group, and for males in the silica NPs high-dose group, APTT was significantly lower than that in the silica MPs high-dose group. For female rats in the silica MPs low-and high-dose groups and the silica NPs low-and middle-dose groups, the level of Na was significantly lower than that in the control group. For females in the silica NPs high-dose group, the level of Cl was significantly lower than that in the control group and silica MPs high-dose group. For male rats in the silica MPs middle-and high-dose group, TP concentration was higher than that in the control group, for males in the silica NPs low-dose group, TP concentration was higher than that in the control and silica MPs low-dose groups, and Na was higher than that in the silica MPs low-dose group. For males in the silica NPs high-dose group, ALB was lower than that in the control group. No significant differences were observed in the serum levels of T3 and TSH. The serum level of T4 in the silica NPs female high-dose group was statistically significantly higher than that in the control group and silica MPs high-dose group.
-
There were no remarkable gross pathological alterations in any of the animals. No statistically significant differences in all absolute organ weights and relative organ weights (organ-to-body weight ratios) in the treatment groups of either males or females were found (Table S1 available in www.besjournal.com).
Table Table S1. Absolute and Relative Organ Weights for Rats after 90 days Oral Administration of Silica MPs and Silica NPs
Parameters Control Silica MPs, mg/(kg·bw) Silica NPs, mg/(kg·bw) 166.7 500 1, 500 166.7 500 1, 500 Female Liver (g) 8.23 ± 1.20 8.03 ± 0.74 7.34 ± 0.48 7.52 ± 1.08 7.39 ± 0.55 7.68 ± 0.83 7.24 ± 0.68 Liver (%) 2.82 ± 0.26 2.83 ± 0.19 2.65 ± 0.17 2.67 ± 0.17 2.73 ± 0.12 2.68 ± 0.21 2.69 ± 0.31 Kidneys (g) 2.03 ± 0.30 2.13 ± 0.22 1.96 ± 0.18 2.00 ± 0.18 2.04 ± 0.08 2.14 ± 0.20 1.94 ± 0.12 Kidneys (%) 0.69 ± 0.08 0.75 ± 0.05 0.71 ± 0.06 0.71 ± 0.03 0.76 ± 0.04 0.75 ± 0.05 0.72 ± 0.07 Spleen (g) 0.63 ± 0.04 0.65 ± 0.06 0.63 ± 0.10 0.63 ± 0.07 0.60 ± 0.08 0.67 ± 0.10 0.66 ± 0.07 Spleen (%) 0.22 ± 0.03 0.23 ± 0.02 0.23 ± 0.04 0.22 ± 0.01 0.22 ± 0.03 0.23 ± 0.03 0.24 ± 0.03 Heart (g) 1.15 ± 0.14 1.13 ± 0.09 1.05 ± 0.06 1.11 ± 0.13 1.09 ± 0.05 1.15 ± 0.13 1.05 ± 0.07 Heart (%) 0.42 ± 0.07 0.40 ± 0.03 0.38 ± 0.03 0.39 ± 0.02 0.40 ± 0.02 0.40 ± 0.04 0.39 ± 0.03 Brain (g) 1.83 ± 0.14 1.81 ± 0.08 1.82 ± 0.12 1.83 ± 0.06 1.86 ± 0.09 1.87 ± 0.07 1.86 ± 0.06 Brain (%) 0.63 ± 0.06 0.64 ± 0.04 0.66 ± 0.06 0.66 ± 0.07 0.69 ± 0.07 0.66 ± 0.04 0.69 ± 0.05 Thymus (g) 0.51 ± 0.12 0.57 ± 0.15 0.50 ± 0.09 0.48 ± 0.10 0.45 ± 0.13 0.52 ± 0.10 0.49 ± 0.11 Thymus (%) 0.18 ± 0.04 0.20 ± 0.04 0.18 ± 0.03 0.17 ± 0.03 0.17 ± 0.04 0.18 ± 0.03 0.18 ± 0.04 Ovaries (g) 0.22 ± 0.03 0.21 ± 0.08 0.20 ± 0.04 0.19 ± 0.05 0.19 ± 0.04 0.20 ± 0.03 0.21 ± 0.04 Ovaries (%) 0.08 ± 0.01 0.07 ± 0.03 0.07 ± 0.01 0.07 ± 0.01 0.07 ± 0.02 0.07 ± 0.01 0.08 ± 0.01 Uterus (g) 0.64 ± 0.13 0.58 ± 0.17 0.59 ± 0.17 0.59 ± 0.16 0.64 ± 0.15 0.68 ± 0.18 0.71 ± 0.16 Uterus (%) 0.22 ± 0.07 0.20 ± 0.06 0.21 ± 0.06 0.21 ± 0.05 0.24 ± 0.06 0.24 ± 0.07 0.27 ± 0.06 Adrenal glands (g) 0.100 ± 0.020 0.104 ± 0.027 0.105 ± 0.039 0.097 ± 0.016 0.101 ± 0.018 0.098 ± 0.016 0.094 ± 0.030 Adrenal glands (%) 0.035 ± 0.008 0.037 ± 0.010 0.038 ± 0.015 0.034 ± 0.004 0.038 ± 0.008 0.034 ± 0.006 0.035 ± 0.011 Thyroid glands (g) 0.022 ± 0.003 0.020 ± 0.002 0.019 ± 0.001 0.022 ± 0.003 0.020 ± 0.001 0.020 ± 0.003 0.021 ± 0.002 Thyroid glands (%) 0.007 ± 0.001 0.007 ± 0.001 0.007 ± 0.001 0.008 ± 0.001 0.007 ± 0.001 0.007 ± 0.001 0.008 ± 0.001 Male Liver (g) 12.60 ± 0.94 12.56 ± 1.11 12.51 ± 1.74 11.45 ± 1.65 11.21 ± 1.88 11.31 ± 1.79 11.20 ± 0.94 Liver (%) 2.71 ± 0.13 2.65 ± 0.14 2.68 ± 0.24 2.60 ± 0.28 2.49 ± 0.22 2.56 ± 0.17 2.50 ± 0.08 Kidneys (g) 3.06 ± 0.20 3.17 ± 0.27 3.11 ± 0.27 3.10 ± 0.29 3.03 ± 0.33 3.02 ± 0.18 2.96 ± 0.25 Kidneys (%) 0.66 ± 0.04 0.67 ± 0.03 0.67 ± 0.06 0.71 ± 0.05 0.68 ± 0.03 0.69 ± 0.06 0.66 ± 0.02 Spleen (g) 0.86 ± 0.13 0.91 ± 0.23 0.81 ± 0.11 0.79 ± 0.09 0.80 ± 0.12 0.83 ± 0.19 0.80 ± 0.15 Spleen (%) 0.18 ± 0.02 0.19 ± 0.04 0.18 ± 0.03 0.18 ± 0.02 0.18 ± 0.02 0.19 ± 0.02 0.18 ± 0.03 Heart (g) 1.66 ± 0.15 1.65 ± 0.19 1.64 ± 0.14 1.58 ± 0.18 1.64 ± 0.15 1.62 ± 0.18 1.64 ± 0.13 Heart (%) 0.36 ± 0.04 0.35 ± 0.02 0.35 ± 0.04 0.36 ± 0.03 0.37 ± 0.04 0.37 ± 0.04 0.37 ± 0.03 Brain (g) 1.92 ± 0.14 2.04 ± 0.03 2.00 ± 0.06 1.98 ± 0.05 1.98 ± 0.14 2.02 ± 0.07 1.99 ± 0.07 Brain (%) 0.42 ± 0.04 0.43 ± 0.02 0.43 ± 0.04 0.45 ± 0.03 0.44 ± 0.04 0.46 ± 0.06 0.45 ± 0.03 Thymus (g) 0.60 ± 0.13 0.68 ± 0.18 0.61 ± 0.18 0.51 ± 0.10 0.49 ± 0.08 0.52 ± 0.18 0.46 ± 0.05 Thymus (%) 0.13 ± 0.02 0.15 ± 0.04 0.13 ± 0.05 0.12 ± 0.02 0.11 ± 0.02 0.12 ± 0.04 0.10 ± 0.01 Testes (g) 3.07 ± 0.49 3.13 ± 0.25 3.10 ± 0.24 3.10 ± 0.19 3.16± 0.21 3.14 ± 0.29 3.05 ± 0.12 Testes (%) 0.66 ± 0.12 0.66 ± 0.05 0.67 ± 0.08 0.71 ± 0.05 0.71± 0.08 0.72 ± 0.08 0.69 ± 0.06 Epididymis (g) 1.28 ± 0.35 1.37 ± 0.14 1.38 ± 0.11 1.38 ± 0.16 1.38 ± 0.17 1.37 ± 0.20 1.40 ± 0.13 Epididymis (%) 0.28 ± 0.07 0.29 ± 0.03 0.30 ± 0.03 0.31 ± 0.05 0.31 ± 0.04 0.31 ± 0.03 0.31 ± 0.03 Adrenal glands (g) 0.080 ± 0.018 0.079 ± 0.025 0.073 ± 0.017 0.078 ± 0.015 0.089 ± 0.020 0.093 ± 0.028 0.079 ± 0.015 Adrenal glands (%) 0.017 ± 0.003 0.017 ± 0.005 0.016 ± 0.004 0.018 ± 0.003 0.020 ± 0.004 0.022 ± 0.007 0.018 ± 0.003 Thyroid glands (g) 0.026 ± 0.002 0.025 ± 0.003 0.024 ± 0.003 0.027 ± 0.003 0.028 ± 0.004 0.026 ± 0.003 0.023 ± 0.002 Thyroid glands (%) 0.006 ± 0.001 0.005 ± 0.001 0.005 ± 0.001 0.006 ± 0.001 0.006 ± 0.001 0.006 ± 0.001 0.005 ± 0.001 The histopathological findings in rats of the control and high-dose groups of silica MPs and silica NPs are summarized in Table 2. The histopathological findings in heart, liver, duodenum, ileum, bladder, and prostate appeared to be incidental, as the frequency and severity of these lesions in silica MPs and silica NPs high-dose groups was comparable with those in the control group. Lesions in these organs included focal myocardial necrosis, mild myocardial fatty degeneration, mild hepatocyte fatty degeneration, hepatocyte spotty necrosis and inflammatory cell infiltrate, epithelial cell autolysis (duodenum and ileum), a small amount of exudate at the mucosal surface of the bladder, interstitial edema, and inflammatory cell infiltrate in the prostate.
Table 2. Histopathological Findings in Rats after 90 Days Oral Administration of Silica MPs and Silica NPs [1, 500 mg/(kg·bw)]
Organs Lesions Control Silica MPs Silica NPs Female Male Female Male Female Male Heart Focal myocardial necrosis 1 0 0 0 0 0 Mild myocardial fatty degeneration 1 0 0 0 0 0 Liver Mild hepatocyte fatty degeneration 6 1 3 1 4 0 Spotty necrosis, inflammatory cell infiltrate 0 0 0 1 0 0 Duodenum Epithelial cell autolysis 3 1 0 0 1 0 Lleum Epithelial cell autolysis 0 0 0 1 0 0 Bladder Small amount of exudate at the mucosal surface 0 1 0 0 0 0 Prostate Interstitial edema, inflammatory cell infiltrate - 0 - 1 - 0 Interstitial inflammatory cell infiltrate - 0 - 0 - 1 Histopathological findings in the lungs of rats in all groups are summarized in Table 3. In the lungs, lesions including mild widening of the alveolar septum, spotty foreign body granulomas, and focal epithelial cell proliferation were found, the frequencies in the high-dose silica groups were higher than those in the control group. Therefore, we conducted a histopathological examination of the lungs in the low-and middle-dose groups of silica MPs and silica NPs. In these lower groups, focal epithelial cell proliferation and foreign body granulomas were also found. The histopathological changes in the lungs are shown in Figure 3.
Figure 3. Histopathological findings in the lungs. (A) Control lung. (B) Foreign body granulomas in the lung, tissues of rats stained with H & E ×100.
Table 3. Histopathological Findings for Lungs of Rats in All Groups after 90 Days Oral Administration of Silica MPs and Silica NPs
Organs Lesions Control Silica MPs Silica NPs Low Middle High Low Middle High F M F M F M F M F M F M F M Lung Mild alveolar septum widening 0 1 0 0 0 0 1 0 0 0 0 1 3 0 Foreign body granulomas 0 0 0 3 3 0 0 3 1 2 1 1 1 0 Focal epithelial cell proliferation 0 0 2 0 2 4 0 3 2 1 1 3 2 1 Note. F, Female; M, Male. -
The distribution of Si in the blood, liver, kidneys and testis is shown in Figure 4. In the liver of female rats, the Si concentrations in the low-and high-dose silica MPs groups, and in the low-, middle-, and high-dose silica NPs groups were lower than those in the control group. In the blood of male rats, the Si concentrations in the middle-dose silica MPs group and low-dose silica NPs group were higher than those in the control group, and the Si concentration in the middle-dose silica NPs group was higher than those in the control and middle-dose silica MPs groups.
doi: 10.3967/bes2018.025
-
Abstract:
Objective To investigate the subchronic oral toxicity of silica nanoparticles (NPs) and silica microparticles (MPs) in rats and to compare the difference in toxicity between two particle sizes. Methods Sprague-Dawley rats were randomly divided into seven groups:the control group; the silica NPs low-, middle-, and high-dose groups; and the silica MPs low-, middle-, and high-dose groups[166.7, 500, and 1, 500 mg/(kg·bw·day)]. All rats were gavaged daily for 90 days, and deionized water was administered to the control group. Clinical observations were made daily, and body weights and food consumption were determined weekly. Blood samples were collected on day 91 for measurement of hematology and clinical biochemistry. Animals were euthanized for necropsy, and selected organs were weighed and fixed for histological examination. The tissue distribution of silicon in the blood, liver, kidneys, and testis were determined. Results There were no toxicologically significant changes in mortality, clinical signs, body weight, food consumption, necropsy findings, and organ weights. Differences between the silica groups and the control group in some hematological and clinical biochemical values and histopathological findings were not considered treatment related. The tissue distribution of silicon was comparable across all groups. Conclusion Our study demonstrated that neither silica NPs nor silica MPs induced toxicological effects after subchronic oral exposure in rats. -
Key words:
- Subchronic toxicity /
- Silica nanoparticles /
- Silica microparticles /
- Rats
-
Figure 2. General observations of subchronic oral toxicity of silica NPs and silica MPs in rats. (A) Mean body weights of rats. (B) Mean food consumption of rats. *Significant difference vs. control group, P < 0.05 (body weight of female rats at the fifth week, food consumption of female rats at the eighth week), #Significant difference vs. silica MPs 166.7 mg/(kg·bw) group, P < 0.05 (food consumption of male rats at the 11th week).
Table 1. Summary of Statistically Significant Hematology and Clinical Biochemical Parameters for Rats after 90 Days Oral Administration of Silica MPs and Silica NPs
Parameters Control Silica MPs, mg/(kg·bw) Silica NPs, mg/(kg·bw) 166.7 500 1, 500 166.7 500 1, 500 Female MCH (pg) 19.1 ± 1.2 18.3 ± 0.7 18.7 ± 0.6 18.5 ± 0.6 18.3 ± 0.6 17.7 ± 1.0* 18.7 ± 0.2 Cl (mmol/L) 120.7 ± 1.8 118.6 ± 2.0 119.6 ± 1.5 121.6 ± 1.1 120.0 ± 1.8 119.0 ± 2.1 118.1 ± 1.4*# Na (mmol/L) 125.1 ± 2.0 120.2 ± 1.2* 121.0 ± 2.5* 123.8 ± 2.7 122.2 ± 2.3* 122.6 ± 1.0 121.6 ± 1.0* T4 (ng/mL) 28.1 ± 6.6 30.8 ± 7.6 28.5 ± 3.9 27.8 ± 7.7 23.7 ± 7.2 32.1 ± 12.9 39.5 ± 6.4*# Male PT (s) 10.0 ± 0.4 10.0 ± 0.3 9.6 ± 0.4 9.9 ± 0.4 10.5 ± 0.5* 9.5 ± 0.3 9.8 ± 0.2 APTT (s) 59.2 ± 3.0 56.5 ± 2.8 58.4 ± 1.9 60.2 ± 1.8 60.1 ± 2.2# 57.3 ± 1.6 57.0 ± 1.9# TP (g/L) 50.9 ± 2.1 49.5 ± 1.7 55.7 ± 3.4* 54.9 ± 2.6* 55.1 ± 1.1*# 54.0 ± 2.4 52.8 ± 3.2 ALB (g/L) 27.0 ± 1.1 26.0 ± 0.9 27.3 ± 1.3 26.8 ± 1.3 26.8 ± 0.9 26.6 ± 1.1 25.3 ± 1.5* Na (mmol/L) 121.8 ± 2.8 121.6 ± 0.9 122.8 ± 2.0 124.0 ± 3.3 124.9 ± 1.5# 122.6 ± 1.5 121.7 ± 1.2 Note.*P < 0.05 as compared with the control group. #P < 0.05 as compared with the silica MPs group. Table S1. Absolute and Relative Organ Weights for Rats after 90 days Oral Administration of Silica MPs and Silica NPs
Parameters Control Silica MPs, mg/(kg·bw) Silica NPs, mg/(kg·bw) 166.7 500 1, 500 166.7 500 1, 500 Female Liver (g) 8.23 ± 1.20 8.03 ± 0.74 7.34 ± 0.48 7.52 ± 1.08 7.39 ± 0.55 7.68 ± 0.83 7.24 ± 0.68 Liver (%) 2.82 ± 0.26 2.83 ± 0.19 2.65 ± 0.17 2.67 ± 0.17 2.73 ± 0.12 2.68 ± 0.21 2.69 ± 0.31 Kidneys (g) 2.03 ± 0.30 2.13 ± 0.22 1.96 ± 0.18 2.00 ± 0.18 2.04 ± 0.08 2.14 ± 0.20 1.94 ± 0.12 Kidneys (%) 0.69 ± 0.08 0.75 ± 0.05 0.71 ± 0.06 0.71 ± 0.03 0.76 ± 0.04 0.75 ± 0.05 0.72 ± 0.07 Spleen (g) 0.63 ± 0.04 0.65 ± 0.06 0.63 ± 0.10 0.63 ± 0.07 0.60 ± 0.08 0.67 ± 0.10 0.66 ± 0.07 Spleen (%) 0.22 ± 0.03 0.23 ± 0.02 0.23 ± 0.04 0.22 ± 0.01 0.22 ± 0.03 0.23 ± 0.03 0.24 ± 0.03 Heart (g) 1.15 ± 0.14 1.13 ± 0.09 1.05 ± 0.06 1.11 ± 0.13 1.09 ± 0.05 1.15 ± 0.13 1.05 ± 0.07 Heart (%) 0.42 ± 0.07 0.40 ± 0.03 0.38 ± 0.03 0.39 ± 0.02 0.40 ± 0.02 0.40 ± 0.04 0.39 ± 0.03 Brain (g) 1.83 ± 0.14 1.81 ± 0.08 1.82 ± 0.12 1.83 ± 0.06 1.86 ± 0.09 1.87 ± 0.07 1.86 ± 0.06 Brain (%) 0.63 ± 0.06 0.64 ± 0.04 0.66 ± 0.06 0.66 ± 0.07 0.69 ± 0.07 0.66 ± 0.04 0.69 ± 0.05 Thymus (g) 0.51 ± 0.12 0.57 ± 0.15 0.50 ± 0.09 0.48 ± 0.10 0.45 ± 0.13 0.52 ± 0.10 0.49 ± 0.11 Thymus (%) 0.18 ± 0.04 0.20 ± 0.04 0.18 ± 0.03 0.17 ± 0.03 0.17 ± 0.04 0.18 ± 0.03 0.18 ± 0.04 Ovaries (g) 0.22 ± 0.03 0.21 ± 0.08 0.20 ± 0.04 0.19 ± 0.05 0.19 ± 0.04 0.20 ± 0.03 0.21 ± 0.04 Ovaries (%) 0.08 ± 0.01 0.07 ± 0.03 0.07 ± 0.01 0.07 ± 0.01 0.07 ± 0.02 0.07 ± 0.01 0.08 ± 0.01 Uterus (g) 0.64 ± 0.13 0.58 ± 0.17 0.59 ± 0.17 0.59 ± 0.16 0.64 ± 0.15 0.68 ± 0.18 0.71 ± 0.16 Uterus (%) 0.22 ± 0.07 0.20 ± 0.06 0.21 ± 0.06 0.21 ± 0.05 0.24 ± 0.06 0.24 ± 0.07 0.27 ± 0.06 Adrenal glands (g) 0.100 ± 0.020 0.104 ± 0.027 0.105 ± 0.039 0.097 ± 0.016 0.101 ± 0.018 0.098 ± 0.016 0.094 ± 0.030 Adrenal glands (%) 0.035 ± 0.008 0.037 ± 0.010 0.038 ± 0.015 0.034 ± 0.004 0.038 ± 0.008 0.034 ± 0.006 0.035 ± 0.011 Thyroid glands (g) 0.022 ± 0.003 0.020 ± 0.002 0.019 ± 0.001 0.022 ± 0.003 0.020 ± 0.001 0.020 ± 0.003 0.021 ± 0.002 Thyroid glands (%) 0.007 ± 0.001 0.007 ± 0.001 0.007 ± 0.001 0.008 ± 0.001 0.007 ± 0.001 0.007 ± 0.001 0.008 ± 0.001 Male Liver (g) 12.60 ± 0.94 12.56 ± 1.11 12.51 ± 1.74 11.45 ± 1.65 11.21 ± 1.88 11.31 ± 1.79 11.20 ± 0.94 Liver (%) 2.71 ± 0.13 2.65 ± 0.14 2.68 ± 0.24 2.60 ± 0.28 2.49 ± 0.22 2.56 ± 0.17 2.50 ± 0.08 Kidneys (g) 3.06 ± 0.20 3.17 ± 0.27 3.11 ± 0.27 3.10 ± 0.29 3.03 ± 0.33 3.02 ± 0.18 2.96 ± 0.25 Kidneys (%) 0.66 ± 0.04 0.67 ± 0.03 0.67 ± 0.06 0.71 ± 0.05 0.68 ± 0.03 0.69 ± 0.06 0.66 ± 0.02 Spleen (g) 0.86 ± 0.13 0.91 ± 0.23 0.81 ± 0.11 0.79 ± 0.09 0.80 ± 0.12 0.83 ± 0.19 0.80 ± 0.15 Spleen (%) 0.18 ± 0.02 0.19 ± 0.04 0.18 ± 0.03 0.18 ± 0.02 0.18 ± 0.02 0.19 ± 0.02 0.18 ± 0.03 Heart (g) 1.66 ± 0.15 1.65 ± 0.19 1.64 ± 0.14 1.58 ± 0.18 1.64 ± 0.15 1.62 ± 0.18 1.64 ± 0.13 Heart (%) 0.36 ± 0.04 0.35 ± 0.02 0.35 ± 0.04 0.36 ± 0.03 0.37 ± 0.04 0.37 ± 0.04 0.37 ± 0.03 Brain (g) 1.92 ± 0.14 2.04 ± 0.03 2.00 ± 0.06 1.98 ± 0.05 1.98 ± 0.14 2.02 ± 0.07 1.99 ± 0.07 Brain (%) 0.42 ± 0.04 0.43 ± 0.02 0.43 ± 0.04 0.45 ± 0.03 0.44 ± 0.04 0.46 ± 0.06 0.45 ± 0.03 Thymus (g) 0.60 ± 0.13 0.68 ± 0.18 0.61 ± 0.18 0.51 ± 0.10 0.49 ± 0.08 0.52 ± 0.18 0.46 ± 0.05 Thymus (%) 0.13 ± 0.02 0.15 ± 0.04 0.13 ± 0.05 0.12 ± 0.02 0.11 ± 0.02 0.12 ± 0.04 0.10 ± 0.01 Testes (g) 3.07 ± 0.49 3.13 ± 0.25 3.10 ± 0.24 3.10 ± 0.19 3.16± 0.21 3.14 ± 0.29 3.05 ± 0.12 Testes (%) 0.66 ± 0.12 0.66 ± 0.05 0.67 ± 0.08 0.71 ± 0.05 0.71± 0.08 0.72 ± 0.08 0.69 ± 0.06 Epididymis (g) 1.28 ± 0.35 1.37 ± 0.14 1.38 ± 0.11 1.38 ± 0.16 1.38 ± 0.17 1.37 ± 0.20 1.40 ± 0.13 Epididymis (%) 0.28 ± 0.07 0.29 ± 0.03 0.30 ± 0.03 0.31 ± 0.05 0.31 ± 0.04 0.31 ± 0.03 0.31 ± 0.03 Adrenal glands (g) 0.080 ± 0.018 0.079 ± 0.025 0.073 ± 0.017 0.078 ± 0.015 0.089 ± 0.020 0.093 ± 0.028 0.079 ± 0.015 Adrenal glands (%) 0.017 ± 0.003 0.017 ± 0.005 0.016 ± 0.004 0.018 ± 0.003 0.020 ± 0.004 0.022 ± 0.007 0.018 ± 0.003 Thyroid glands (g) 0.026 ± 0.002 0.025 ± 0.003 0.024 ± 0.003 0.027 ± 0.003 0.028 ± 0.004 0.026 ± 0.003 0.023 ± 0.002 Thyroid glands (%) 0.006 ± 0.001 0.005 ± 0.001 0.005 ± 0.001 0.006 ± 0.001 0.006 ± 0.001 0.006 ± 0.001 0.005 ± 0.001 Table 2. Histopathological Findings in Rats after 90 Days Oral Administration of Silica MPs and Silica NPs [1, 500 mg/(kg·bw)]
Organs Lesions Control Silica MPs Silica NPs Female Male Female Male Female Male Heart Focal myocardial necrosis 1 0 0 0 0 0 Mild myocardial fatty degeneration 1 0 0 0 0 0 Liver Mild hepatocyte fatty degeneration 6 1 3 1 4 0 Spotty necrosis, inflammatory cell infiltrate 0 0 0 1 0 0 Duodenum Epithelial cell autolysis 3 1 0 0 1 0 Lleum Epithelial cell autolysis 0 0 0 1 0 0 Bladder Small amount of exudate at the mucosal surface 0 1 0 0 0 0 Prostate Interstitial edema, inflammatory cell infiltrate - 0 - 1 - 0 Interstitial inflammatory cell infiltrate - 0 - 0 - 1 Table 3. Histopathological Findings for Lungs of Rats in All Groups after 90 Days Oral Administration of Silica MPs and Silica NPs
Organs Lesions Control Silica MPs Silica NPs Low Middle High Low Middle High F M F M F M F M F M F M F M Lung Mild alveolar septum widening 0 1 0 0 0 0 1 0 0 0 0 1 3 0 Foreign body granulomas 0 0 0 3 3 0 0 3 1 2 1 1 1 0 Focal epithelial cell proliferation 0 0 2 0 2 4 0 3 2 1 1 3 2 1 Note. F, Female; M, Male. -
[1] OECD. SIDS Dossier on Synthetic Amorphous Silica and Silicates. 2004. https: //hpvchemicals. oecd. org/UI/handler. axd?id=81d3694a-a582-4fa8-a8f2-f771459b67ed, [2018-01-25]. [2] Dekkers S, Krystek P, Peters RJ, et al. Presence and risks of nanosilica in food products. Nanotoxicology, 2011; 5, 393-405. doi: 10.3109/17435390.2010.519836 [3] Dekkers S, Bouwmeester H, Bos PM, et al. Knowledge gaps in risk assessment of nanosilica in food:evaluation of the dissolution and toxicity of different forms of silica. Nanotoxicology, 2013; 7, 367-77. doi: 10.3109/17435390.2012.662250 [4] World Health Organization (WHO). Evaluation of the Joint FAO/WHO Expert Committee on Food Additives (JECFA). Silicon dioxide, amorphous. 1985. http://apps.who.int/foodadditives-contaminants-jecfa-database/chemical.aspx?chemID=2462, [2018-01-25]. [5] Athinarayanan J, Periasamy VS, Alsaif MA, et al. Presence of nanosilica (E551) in commercial food products:TNF-mediated oxidative stress and altered cell cycle progression in human lung fibroblast cells. Cell Biol Toxicol, 2014; 30, 89-100. doi: 10.1007/s10565-014-9271-8 [6] Hansen SF, Michelson ES, Kamper A, et al. Categorization framework to aid exposure assessment of nanomaterials in consumer products. Ecotoxicology, 2008; 17, 438-47. doi: 10.1007/s10646-008-0210-4 [7] Lim JH, Sisco P, Mudalige TK, et al. Detection and characterization of SiO2 and TiO2 naostructures in dietary supplements. J Agric Food Chem, 2015; 63, 3144-52. doi: 10.1021/acs.jafc.5b00392 [8] Xu L, Liu Y, Bai R, et al. Applications and toxicological issues surrounding nanotechnology in the food industry. Pure Appl Chem, 2010; 82, 349-72. doi: 10.1351/PAC-CON-09-05-09 [9] Tarantini A, Huet S, Jarry G, et al. Genotoxicity of synthetic amorphous silica nanoparticles in rats following short-term exposure. Part 1:oral route. Environ Mol Mutagen, 2015; 56, 218-27. doi: 10.1002/em.v56.2 [10] EFSA. Scientific opionion on Guidance on the risk assessment of the applicaiton of nanoscience and nanotechnologies in the food and feed chain. EFSA Journal, 2011; 9, 2140. doi: 10.2903/j.efsa.2011.2140 [11] Food and Agriculture Organization of the United Nations and World Health Organization (FAO and WHO). FAO/WHO technical paper: State of the art on the initiatives and activities relevant to risk assessment and risk management of nanotechnologies in the food and agriculture sectors. Rome. FAO/WHO. 2013; 1-46. [12] Food and Drug Administration (FDA). Guidance for Industry: Assessing the effects of significant manufacturing process changes, including emerging technologies, on the safety and regulatory status of food ingredients and food contact substaces, including food ingredients that are color additives. USA FDA. 2014; 1-29. [13] OECD. OECD Environment, Health and Safety Publications Series on the Safety of Manufactured Nanomaterials. No. 25: Guidance Manual for the Testing of Manufactured Nanomaterials: OECD's sponsorship programme; first revision. Organisation for Economic Cooperation and Development. Paris, 2010; 1-92. [14] Ruby MV, Davis A, Schoof R, et al. Estimation of Lead and Arsenic Bioavailability Using a Physiologically Based Extraction Test. Environ Sci Technol, 1996; 30, 422-30. doi: 10.1021/es950057z [15] Cave MR, Wragg J, Palumbo B, et al. Measurement of the Bioaccessibility of Arsenic in UK Soils. R & D Technical Report P5-062/TR02. Environment Agency, Bristol, 2003; 1-108. doi: 10.1007/s10653-010-9324-8 [16] OECD. OECD guidelines for the testing of chemicals, Section 4:Health Effects, Test No. 408:Repeated Dose 90-day Oral Toxicity Study in Rodents. Organisation for Economic Cooperation and Development, 1998; 1-10. http://www.oecd.org/env/ehs/testing/section4-health-effects.htm [17] Magnuson BA, Jonaitis TS, Card JW. A brief review of the occurrence, use, and safety of food-related nanomaterials. J Food Sci, 2011; 76, R126-33. doi: 10.1111/jfds.2011.76.issue-6 [18] Gerloff K, Pereira DIA, Faria N, et al. Influence of simulated gastro-intestinal conditions on particle-induced cytotoxicity and interleukin-8 regulation in differentiated and undifferentiated Caco-2 cells. Nanotoxicology, 2013; 7, 353-66. doi: 10.3109/17435390.2012.662249 [19] Kim MK, Lee JA, Jo MR, et al. Bioavailability of Silica, Titanium Dioxide, and Zinc Oxide Nanoparticles in Rats. J Nanosci Nanotechnol, 2016; 16, 6580-6. doi: 10.1166/jnn.2016.12350 [20] Lee JA, Kim MK, Song JH, et al. Biokinetics of food additive silica nanoparticles and their interactions with food components. Colloids Surf B Biointerfaces, 2017; 150, 384-92. doi: 10.1016/j.colsurfb.2016.11.001 [21] Liu X, Sun J. Time-course effects of intravenously administrated silica nanoparticles on blood coagulation and endothelial function in rats. J Nanosci Nanotechnol, 2013; 13, 222-8. doi: 10.1166/jnn.2013.6910 [22] Nabeshi H, Yoshikawa T, Matsuyama K, et al. Amorphous nanosilicas induce consumptive coagulopathy after systemic exposure. Nanotechnology, 2012; 23, 045101. doi: 10.1088/0957-4484/23/4/045101 [23] Yoshida T, Yoshioka Y, Tochigi S, et al. Intranasal exposure to amorphous nanosilica particles could activate intrinsic coagulation cascade and platelets in mice. Part Fibre Toxicol, 2013; 10, 41. doi: 10.1186/1743-8977-10-41 [24] Menjo M, Yamaguchi S, Murata Y, et al. Responsiveness to thyroid hormone is enhanced in rat hepatocytes cultured as spheroids compared with that in monolayers:altered responsiveness to thyroid hormone possibly involves complex formed on thyroid hormone response elements. Thyroid, 1999; 9, 959-67. doi: 10.1089/thy.1999.9.959 [25] Cho WS, Choi M, Han BS, et al. Inflammatory mediators induced by intratracheal instillation of ultrafine amorphous silica particles. Toxicol Lett, 2007; 175, 24-33. doi: 10.1016/j.toxlet.2007.09.008 [26] Freire J, Ajona D, de Biurrun G, et al. Silica-induced chronic inflammation promotes lung carcinogenesis in the context of an immunosuppressive microenvironment. Neoplasia, 2013; 15, 913-24. doi: 10.1593/neo.13310 [27] Langley R, Mishra N, Peña-Philippides J, et al. Granuloma formation induced by low-dose chronic silica inhalation is associated with an anti-apoptotic response in Lewis rats. J Toxicol Environ Health A, 2010; 73, 669-83. doi: 10.1080/15287390903578521 [28] Lee JA, Kim MK, Paek HJ, et al. Tissue distribution and excretion kinetics of orally administered silica nanoparticles in rats. Int J Nanomedicine, 2014; 9(Suppl 2), 251-60. [29] So SJ, Jang IS, Han CS. Effect of micro/nano silica particle feeding for mice. J Nanosci Nanotechnol, 2008; 8, 5367-71. doi: 10.1166/jnn.2008.1347 [30] Yun JW, Kim SH, You JR, et al. Comparative toxicity of silicon dioxide, silver and iron oxide nanoparticles after repeated oral administration to rats. J Appl Toxicol, 2015; 35, 681-93. doi: 10.1002/jat.v35.6 [31] Paek HJ, Chung HE, Lee JA, et al. Quantitative Determination of Silica Nanoparticles in Biological Matrices and Their Pharmacokinetics and Toxicokinetics in Rats. Sci Adv Mater, 2014; 6, 1605-10. doi: 10.1166/sam.2014.1817 [32] van der Zande M, Vandebriel RJ, Groot MJ, et al. Sub-chronic toxicity study in rats orally exposed to nanostructured silica. Part Fibre Toxicol, 2014; 11, 8. doi: 10.1186/1743-8977-11-8 [33] Fu C, Liu T, Li L, et al. The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes. Biomaterials, 2013; 34, 2565-75. doi: 10.1016/j.biomaterials.2012.12.043 [34] Lin B, Xi Z, Zhang Y, et al. Primary study on the hepatotoxicity and nephrotoxicity of rats induced by three kinds of nanomaterials. Journal of Hygiene Research, 2008; 37, 651-3. [35] Kim YR, Lee SY, Lee EJ, et al. Toxicity of colloidal silica nanoparticles administered orally for 90 days in rats. Int J Nanomedicine, 2014; 9(Suppl 2), 67-78. [36] Buesen R, Landsiedel R, Sauer UG, et al. Effects of SiO2, ZrO2, and BaSO4 nanomaterials with or without surface functionalization upon 28-day oral exposure to rats. Arch Toxicol, 2014; 88, 1881-906. doi: 10.1007/s00204-014-1337-0 [37] Kim JH, Kim CS, Ignacio RMC, et al. Immunotoxicity of silicon dioxide nanoparticles with different sizes and electrostatic charge. Int J Nanomedicine, 2014; 9(Suppl 2), 183-93. [38] Cristo LD, Movia D, Bianchi MG, et al. Proinflammatory Effects of Pyrogenic and Precipitated Amorphous Silica Nanoparticles in Innate Immunity Cells. Toxicol Sci, 2016; 150, 40-53. doi: 10.1093/toxsci/kfv258 [39] Tarantini A, Huet S, Jarry G, et al. Genotoxicity of synthetic amorphous silica nanoparticles in rats following short-term exposure. Part 1:oral route. Environ Mol Mutagen, 2015; 56, 218-27. doi: 10.1002/em.v56.2 [40] Hofmann T, Schneider S, Wolterbeek A, et al. Prenatal toxicity of synthetic amorphous silica nanomaterial in rats. Reprod Toxicol, 2015; 56, 141-6. doi: 10.1016/j.reprotox.2015.04.006 [41] Wolterbeek A, Oosterwijk T, Schneider S, et al. Oral two-generation reproduction toxicity study with NM-200 synthetic amorphous silica in Wistar rats. Reprod Toxicol, 2015; 56, 147-54. doi: 10.1016/j.reprotox.2015.03.006 [42] Narciso L, Tassinari R, Cordelli E, et al. Effects of synthetic amorphous silica nanoparticle (NM-203) on male and female reproductive systems following 90-days repeated-dose oral administration in rat. Reprod Toxicol, 2016; 64, 42-3. https://www.researchgate.net/profile/Patrizia_Eleuteri2 [43] Peters R, Kramer E, Oomen AG, et al. Presence of nano-sized silica during in vitro digestion of foods containing silica as a food additive. Acs Nano, 2012; 6, 2441-51. doi: 10.1021/nn204728k [44] Sakai-Kato K, Hidaka M, Un K, et al. Physicochemical properties and in vitro intestinal permeability properties and intestinal cell toxicity of silica particles, performed in simulated gastrointestinal fluids. Biochim Biophys Acta, 2014; 1840, 1171-80. doi: 10.1016/j.bbagen.2013.12.014